ABCAM Plc Directorate Change (8275K)

TIDMABC

RNS Number : 8275K

ABCAM Plc

30 June 2014

 
 For immediate release   30 June 2014 
 

ABCAM PLC

("Abcam" or "the Company")

Directorate Change

Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of innovative protein research tools, announces that, after five years as Abcam's Chairman, Mike Redmond has decided to step down from the Board following the Annual General Meeting, which will be held later this year. He will be succeeded as Chairman by Murray Hennessy, who has served as a Non-Executive Director at Abcam for the past three years.

Jonathan Milner, Abcam's Chief Executive Officer, said:"Mike's insight and leadership have been instrumental in Abcam's successful growth over the past five years. On behalf of the Board I would like to extend our sincerest thanks and gratitude to him. After three years on the Board, Murray knows Abcam very well and his experience in international customer-facing industries and online businesses in particular make him the ideal candidate to take over from Mike later in the year and help lead Abcam's next phase of growth."

 
Abcam                                      + 44 (0) 1223 696 000 
Jonathan Milner, Chief Executive Officer 
 Jeff Iliffe, Chief Financial Officer 
Numis Securities - Nominated Adviser 
 & Joint Broker                            + 44 (0) 20 7260 1000 
Michael Meade - Nominated Adviser 
James Black - Corporate Broking 
Peel Hunt LLP - Joint Broker               + 44 (0) 20 7418 8900 
Clare Terlouw / Jock Maxwell MacDonald 
Buchanan                                   + 44 (0) 20 7466 5000 
Mark Court / Fiona Henson / Sophie 
 Cowles 
 

Notes for editors:

About Abcam plc

Abcam plc is a leading provider of protein research tools and services, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level to improve the understanding of health and disease.

Abcam is committed to providing scientists with access to the correct reagents and tools for their research. The Company's catalogue currently comprises more than 130,000 products and is continually evolving to meet customer needs. The range offered includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam products are supported by detailed, up-to-date and unbiased data on our website.

Headquartered in Cambridge, UK, Abcam has nine global subsidiary offices and ships to over 100 countries. The Company was founded in 1998, and now employs over 700 people. Abcam is quoted on the AIM market of the London Stock Exchange (AIM: ABC).

To find out more, please visit www.abcam.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOAKMGZVVNGGDZM